【プレスリリースメモ】 RNAi関係 (2013.6.10)  

<Alnylam Pharmaceuticals>
Alnylam to Webcast Presentation at Goldman Sachs 34th Annual Global Healthcare Conference(2013.6.6)

Key Mesenchymal Precursor Cell Patent Granted in Japan(2013.6.5)

<Antisense Therapeutics>
ATL1102 for MS – Dosing Starts in Key Toxicology Study(2013.6.4)

Benitec Selects CRO for European Lung Cancer Trial(2013.6.3)
Trading Halt(2013.6.3)
Benitec raises A$7m through Private Placement(2013.6.6)
Lodge Partners notes ‘very exciting time’ for Benitec and maintains ‘buy’ recommendation(2013.6.6)

<Bio-Path Holdings>
Bio-Path Holdings Successfully Completes Fifth Cohort in Phase I Clinical Trial of Lead Candidate Liposomal Grb-2 in Leukemia(2013.6.6)

<CytRx Corporation>
CytRx Announces the Presentation of Favorable Results from Novel Combination of Aldoxorubicin and Doxorubicin in a Phase 1b Clinical Trial at ASCO Conference(2013.6.3)

<Exiqon A/S>
Exiqon A/S - Exiqon and Asuragen sign agreement for real-time PCR services.(2013.6.10)

<Galena Biopharma>
Galena Biopharma Provides Product Pipeline Update at the ASCO 2013 Annual Meeting(2013.6.3)

<Generex Biotechnology>
Generex Announces ASCO Presentations of AE37 Vaccine Data; Potential Leading Immunotherapy Option for Breast Cancer Patients(2013.6.5)

<Idera Pharmaceuticals>
Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis(2013.6.5)

<Isis Pharmaceuticals>
Isis Pharmaceuticals Earns $10 Million Milestone Payment from AstraZeneca for ISIS-AR Rx to Treat Prostate Cancer(2013.6.3)
Isis Pharmaceuticals Reports Encouraging Data on ISIS-STAT3rx in Patients With Cancer(2013.6.3)
Isis Pharmaceuticals to Present at the Goldman Sachs 34th Annual Global Healthcare Conference(2013.6.5)
Isis Pharmaceuticals Earns $6 Million Payment from AstraZeneca(2013.6.6)
Xenon Licenses Antisense Drug XEN701 From Isis and Initiates Preclinical Toxicology Studies(2013.6.10)

<Mirna Therapeutics>
Mirna Therapeutics Appoints Dr. Sinil Kim as Chief Medical Officer(2013.6.4)

CEO Remuneration and Employee Performance Rights(2013.6.7)

<Rosetta Genomics>
Rosetta Genomics to Increase the Number of U.S. Sales Territories(2013.6.4)
Rosetta Genomics Announces Acceptance for Publication by Molecular Cancer of Rosetta Cancer Origin Test Manuscript(2013.6.6)
Rosetta Genomics Executes Credentialing Agreement with Three Rivers Provider Network(2013.6.7)

<RXi Pharmaceuticals>
RXi Pharmaceuticals Announces Positive Results in its First Double Blind Study in Healthy Volunteers with RXI-109(2013.6.6)

<Sarepta Therapeutics>
Sarepta Therapeutics to Present Company Overview at the Wells Fargo Securities 2013 Healthcare Conference(2013.6.5)

<Silence Therapeutics>
Notice of General Meeting and Annual Report(2013.6.3)

<Valeant Pharmaceuticals>
Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus(2013.6.7)

第24 回新株予約権(第三者割当て)(行使価額修正条項付)の月間行使状況に関するお知らせ(2013.6.3)
「ナグラザイム」の販売本数が 4,000 バイアルに到達(2013.6.7)

[ 2013/06/10 23:48 ] プレスリリース | TB(0) | CM(0)

07 ≪│2018/08│≫ 09
- - - 1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31 -